PLN 40.0
(-7.83%)
Year | Operating Income | Operating Income Growth |
---|---|---|
2023 | -16.86 Million PLN | -222.29% |
2022 | -5.23 Million PLN | -50.34% |
2021 | -3.48 Million PLN | -264.4% |
2020 | -955 Thousand PLN | -40.44% |
2019 | -680 Thousand PLN | 46.03% |
2018 | -1.26 Million PLN | 0.0% |
Year | Operating Income | Operating Income Growth |
---|---|---|
2024 Q1 | -3.81 Million PLN | 26.44% |
2024 Q2 | -5.31 Million PLN | -39.12% |
2023 Q2 | -4.36 Million PLN | -102.65% |
2023 Q4 | -5.19 Million PLN | -0.68% |
2023 FY | -16.86 Million PLN | -222.29% |
2023 Q1 | -2.15 Million PLN | -715.15% |
2023 Q3 | -5.15 Million PLN | -18.25% |
2022 FY | -5.23 Million PLN | -50.34% |
2022 Q4 | -264 Thousand PLN | 81.29% |
2022 Q3 | -1.41 Million PLN | -1841.98% |
2022 Q2 | 81 Thousand PLN | 107.15% |
2022 Q1 | -1.13 Million PLN | 40.65% |
2021 Q1 | -377 Thousand PLN | -57.74% |
2021 FY | -3.48 Million PLN | -264.4% |
2021 Q4 | -1.9 Million PLN | -107.5% |
2021 Q3 | -920 Thousand PLN | -235.77% |
2021 Q2 | -274 Thousand PLN | 27.32% |
2020 Q2 | -262 Thousand PLN | 0.0% |
2020 Q3 | -193 Thousand PLN | 26.34% |
2020 Q4 | -239 Thousand PLN | -23.83% |
2020 FY | -955 Thousand PLN | -40.44% |
2020 Q1 | -262 Thousand PLN | 0.0% |
2019 FY | -680 Thousand PLN | 46.03% |
2018 FY | -1.26 Million PLN | 0.0% |
Name | Operating Income | Operating Income Difference |
---|---|---|
Bioceltix S.A. | -15.81 Million PLN | -6.59% |
BIOTON S.A. | 15.29 Million PLN | 210.245% |
Captor Therapeutics Spolka Akcyjna | -73.01 Million PLN | 76.906% |
Mabion S.A. | 55.06 Million PLN | 130.624% |
Molecure S.A. | -22.1 Million PLN | 23.714% |
NanoGroup S.A. | -7.9 Million PLN | -113.392% |
Pharmena S.A. | 34.87 Million PLN | 148.355% |
Pure Biologics Spólka Akcyjna | -31.71 Million PLN | 46.838% |
Ryvu Therapeutics S.A. | -100.94 Million PLN | 83.296% |
Synthaverse S.A. | 8.64 Million PLN | 295.004% |
Urteste S.A. | -6.44 Million PLN | -161.548% |